Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 07-22 21:33:11时区推断·⟳ 抓取 07-22 21:34:29·⚡ 决策 07-23 08:34:55 +11h00m·96.5 天前
Arrowhead股价创52周高位并回顾近期三期积极数据
正文核心是股价触及52周高位87.93美元、过去一年上涨368.09%，并复述近期plozasiran三期数据。
📄 原文Investing.com↗ 原文
Arrowhead Pharmaceuticals stock hits 52-week high at $87.93
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven? Arrowhead Pharmaceuticals Inc. stock has…
不做 Arrowhead Pharmaceuticals（ARWR.US）
这是股价高位和旧临床进展汇总，不是新增可交易催化；且价格已大幅反应。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 medium · price-in 风险 high ↗
关键理由
- 正文核心是股价触及52周高位87.93美元、过去一年上涨368.09%，并复述近期plozasiran三期数据。
主要风险
- 当前条目是行情和旧进展汇总，不是新的临床读出、监管批准或商业化里程碑。
原文全文
展开原文 · 2,346 字
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
Arrowhead Pharmaceuticals Inc. stock has reached a 52-week high, hitting $87.93, with shares currently trading at $88.58 and the company commanding a market cap of $10.5 billion. According to InvestingPro data, the stock is trading near its 52-week high of $87.83. This milestone comes as the company experiences a remarkable 1-year change of 368.09%. The biotechnology firm, known for its innovative RNA interference therapeutics, has seen its stock price surge over the past year, reflecting investor confidence and potential growth in its pipeline. Yet InvestingPro Tips reveal analysts don’t anticipate profitability this year, with the stock trading at a high Price/Book multiple of 17.1x. InvestingPro’s Fair Value analysis suggests the stock may be overvalued at current levels. For deeper insights, investors can access ARWR’s comprehensive Pro Research Report, one of 1,400+ available on the platform. The 52-week high underscores the positive sentiment surrounding Arrowhead’s advancements and strategic developments in the biotech sector.
In other recent news, Arrowhead Pharmaceuticals announced positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridemia. The studies achieved their primary endpoint, with plozasiran showing significant triglyceride reductions of 79% and 81% at month 12, compared to a 27% reduction with placebo. Stifel initiated coverage on Arrowhead Pharmaceuticals with a buy rating, citing the potential of plozasiran as a best-in-class drug and estimating a $3 billion market opportunity. H.C. Wainwright also reiterated its buy rating on the company following a cardiometabolic research webinar.
Arrowhead Pharmaceuticals presented interim results from a Phase 1/2a trial of ARO-INHBE at the European Association for the Study of the Liver Congress, highlighting reductions in liver fat content in patients with obesity. Additionally, the company shared data indicating that plozasiran may not require dose adjustment for patients with renal or hepatic impairments. These developments were presented at the European Atherosclerosis Society Congress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Arrowhead Pharmaceuticals Inc. stock has reached a 52-week high, hitting $87.93, with shares currently trading at $88.58 and the company commanding a market cap of $10.5 billion. According to InvestingPro data, the stock is trading near its 52-week high of $87.83. This milestone comes as the company experiences a remarkable 1-year change of 368.09%. The biotechnology firm, known for its innovative RNA interference therapeutics, has seen its stock price surge over the past year, reflecting investor confidence and potential growth in its pipeline. Yet InvestingPro Tips reveal analysts don’t anticipate profitability this year, with the stock trading at a high Price/Book multiple of 17.1x. InvestingPro’s Fair Value analysis suggests the stock may be overvalued at current levels. For deeper insights, investors can access ARWR’s comprehensive Pro Research Report, one of 1,400+ available on the platform. The 52-week high underscores the positive sentiment surrounding Arrowhead’s advancements and strategic developments in the biotech sector.
In other recent news, Arrowhead Pharmaceuticals announced positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridemia. The studies achieved their primary endpoint, with plozasiran showing significant triglyceride reductions of 79% and 81% at month 12, compared to a 27% reduction with placebo. Stifel initiated coverage on Arrowhead Pharmaceuticals with a buy rating, citing the potential of plozasiran as a best-in-class drug and estimating a $3 billion market opportunity. H.C. Wainwright also reiterated its buy rating on the company following a cardiometabolic research webinar.
Arrowhead Pharmaceuticals presented interim results from a Phase 1/2a trial of ARO-INHBE at the European Association for the Study of the Liver Congress, highlighting reductions in liver fat content in patients with obesity. Additionally, the company shared data indicating that plozasiran may not require dose adjustment for patients with renal or hepatic impairments. These developments were presented at the European Atherosclerosis Society Congress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。